What’s Old Is New Again: Bristol Cancer Plans Re-Emphasize Cytotoxics
Executive Summary
Bristol-Myers Squibb is aiming to recapture its leadership in oncology by focusing on developing novel cytotoxic agents as well as concentrating on the emerging field of targeted therapies, Chief Scientific Officer Elliott Sigal said during a post-ASCO call
You may also be interested in...
Bristol Looks To New Abilify Uses But Drops Vinflunine Lead Indication
Bristol is gearing up for new growth for its atypical antipsychotic Abilify (aripiprazole) with a new direct-to-consumer advertising campaign and a series of expanded indications
Bristol Looks To New Abilify Uses But Drops Vinflunine Lead Indication
Bristol is gearing up for new growth for its atypical antipsychotic Abilify (aripiprazole) with a new direct-to-consumer advertising campaign and a series of expanded indications
Ixempra Gives Bristol New Start In Chemotherapy, Offers Refinement Of Taxol
With FDA's approval of Ixempra (ixabepilone), Bristol-Myers Squibb is poised to launch a novel chemotherapy option that offers a refinement of its successful Taxol and activity in taxane resistant patients